AdvanTIG-105: a phase I dose escalation study of the anti-TIGIT monoclonal antibody ociperlimab in combination with tislelizumab in patients with advanced solid tumors
=======================================================================================================================================================================

* Sophia Frentzas
* Steven Kao
* Rang Gao
* Hao Zheng
* Ahsan Rizwan
* Nageshwar Budha
* Luz de la Hoz Pedroza
* Wei Tan
* Tarek Meniawy